Amarin Co. plc (NASDAQ:AMRN) Given Average Rating of “Hold” by Analysts

Amarin Co. plc (NASDAQ:AMRNGet Rating) has been assigned a consensus recommendation of “Hold” from the seven research firms that are covering the company, reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $2.50.

AMRN has been the topic of a number of analyst reports. The Goldman Sachs Group lowered their target price on Amarin from $1.75 to $1.50 and set a “sell” rating on the stock in a report on Tuesday, May 24th. raised Amarin from a “sell” rating to a “hold” rating in a research note on Wednesday, July 27th.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Creative Planning raised its position in shares of Amarin by 66.4% in the 2nd quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 6,900 shares during the period. Quantbot Technologies LP purchased a new position in shares of Amarin in the 1st quarter worth $31,000. Winthrop Advisory Group LLC purchased a new position in shares of Amarin in the 1st quarter worth $34,000. Kalos Management Inc. purchased a new position in shares of Amarin in the 1st quarter worth $37,000. Finally, Advisor Resource Council purchased a new position in Amarin in the second quarter valued at about $37,000. 34.15% of the stock is owned by hedge funds and other institutional investors.

Amarin Stock Performance

Shares of NASDAQ:AMRN opened at $1.19 on Tuesday. The business’s fifty day moving average price is $1.36 and its two-hundred day moving average price is $1.98. The stock has a market cap of $479.82 million, a PE ratio of -4.76 and a beta of 1.87. Amarin has a one year low of $1.09 and a one year high of $5.52.

Amarin (NASDAQ:AMRNGet Rating) last announced its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). The company had revenue of $94.44 million for the quarter, compared to analyst estimates of $88.21 million. Amarin had a negative net margin of 21.05% and a negative return on equity of 13.63%. Amarin’s quarterly revenue was down 38.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.02 EPS. As a group, equities research analysts predict that Amarin will post -0.36 earnings per share for the current fiscal year.

About Amarin

(Get Rating)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

See Also

Analyst Recommendations for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with's FREE daily email newsletter.